Avadel pharmaceuticals shares new lumryz™ (sodium oxybate) for extended-release oral suspension (ciii) data at sleep 2024

– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of lumryz –

AVDL Ratings Summary

AVDL Quant Ranking